Angiotensin II Type 2 Receptor Blockade Amplifies the Early Signals of Cardiac Growth Response to Angiotensin II in Hypertrophied Hearts
In contrast with neonatal myocytes, early signals of the cardiac growth response to Ang II in adult rat hearts do not involve the induction of proto-oncogenes, which occurs in response to load. [1] [2] [3] [4] [5] [6] [7] [8] We have also shown that the acute cardiac growth response of new cardiac protein synthesis and PKC translocation in response to Ang II is blunted in hypertrophied hearts with aortic stenosis relative to normal hearts. 2, 3 Recent observations suggest that this may be mediated by the Ang II type 2 (AT 2 ) receptor. We 9 and others 10 have demonstrated an upregulation of LV AT 2 receptors in hypertrophied hearts. Similar upregulation of AT 2 receptors was reported in human failing myocardium. 11, 12 Several studies have proposed that downstream signaling related to the AT 2 receptor differs strikingly from signaling of the AT 1 receptor and involves kinin/cGMP signaling rather than the PKC pathway. [13] [14] [15] [16] [17] Transgenic experiments suggest that the AT 2 receptor signaling cascade has distinct biological roles compared with AT 1 receptor-mediated signaling. 18, 19 Consistent with this hypothesis, recent studies in vascular smooth muscle cells 20 and endothelial cells 21 demonstrated that the AT 2 receptor exerts antiproliferative effects counteracting the growth-promoting effects of the AT 1 receptor. In contrast, the role of AT 2 receptor-mediated signaling in cardiac growth of the intact adult heart is not known. Thus, in the present study, we tested the hypothesis that in hypertrophied hearts, the AT 2 receptor mediates inhibitory effects on the new cardiac protein synthesis and PKC activation in response to acute Ang II stimulation.
Methods
Weanling male Wistar rats (75 to 90 g, Charles River Breeding Laboratories, Wilmington, Del) underwent ascending aortic stenosis as previously described (nϭ44). 2, 3, 9 Age-matched animals served as a control group (nϭ45). At 7 to 9 weeks after the banding, the isolated flaccid hearts were perfused by modified Krebs-Henseleit buffer at 37°C as previously described. 2, 3, [7] [8] [9] For measurements of protein synthesis, the buffer contained 0.05% albumin and a mixture of amino acids as previously described. 2, 3, 8, 9 To investigate the effects of AT 2 blockade on Ang II-induced new cardiac protein synthesis, normal and hypertrophied hearts were perfused with no drug (nϭ4), with Ang II 10 Ϫ8 mol/L plus 10 Ϫ7 mol/L prazosin (nϭ6 to 8), and with Ang II plus the selective AT 2 blocker PD 122319 (Parke-Davis, 5ϫ10 Ϫ7 mol/L, nϭ6 or 7). The ␣ 1 -blocker prazosin was used to prevent any indirect stimulation of protein synthesis via activation of the postsynaptic sympathetic system. 3, 4 The dose of PD 122319 was chosen on the basis of previous studies 9,13,14 demonstrating a selective AT 2 receptor blockade in response to Ang II. After 60 minutes of perfusion, hearts were perfused for another 120 minutes with the same buffer, to which 0.5 mCi/L [ 3 H]phenylalanine was added. 2, 3, 8, 22 The net LV protein synthesis during the 120 minutes of perfusion was assumed to be linear 2, 3, 8, 22 and was calculated as follows: phenylalanine incorporation (moles ⅐ g protein
)/perfusate phenylalanine specific activity (dpm/mol). To investigate whether AT 2 blockade modulates Ang II-stimulated PKC translocation, separate groups of normal and hypertrophied hearts were perfused for 15 minutes with no drug (nϭ4), with Ang II 10 Ϫ8 mol/L plus 10 Ϫ7 mol/L prazosin (nϭ5 or 6), and with Ang II plus the AT 2 blocker 5ϫ10 Ϫ7 mol/L (nϭ6 or 7). This time period was chosen on the basis of the time course of maximal activation of PKC by Ang II. 2 Cytosolic and membrane fractions from frozen LV tissue were prepared as described previously. 2, 23 Samples containing 50 g protein were then separated on a 7.5% SDS-PAGE gel. Detection of PKC was carried out by use of anti-PKC-⑀ antibody (1:1000, Life Technologies) and an enzymelinked chemiluminescence-Western blotting analysis system (Amersham International).
To investigate whether AT 2 blockade modifies LV cGMP content in Ang II-perfused hearts, additional groups of normal and hypertrophied hearts were subjected to Ang II 10 Ϫ8 mol/L plus 10 Ϫ7 mol/L prazosin (nϭ4 per group) and to Ang II plus the AT 2 blocker 5ϫ10 Ϫ7 mol/L (nϭ5 per group). LV cGMP levels were determined by enzymatic assay (Amersham, Life Science) and expressed as mol/mg protein.
All data are presented as meanϮSEM. Two-way ANOVA followed by Fisher's exact test for post hoc analyses was used for multiple comparisons. Significance was accepted at PϽ0.05.
Results

Characteristics of Hypertrophied and Normal Hearts
There was an 80% to 90% increase in LV weight in aortic stenosis versus normal hearts (Table) . By study design, coronary flow was adjusted at baseline to achieve a similar coronary flow per gram in hypertrophied and normal hearts (Table) .
Effects of AT 2 Blockade on Ang II-Induced Phenylalanine Incorporation
The rate of [ 3 H]phenylalanine incorporation into proteins in the absence of drug was similar in normal and hypertrophied hearts ( Figure 1 ). Corroborating our previous findings, 2 Ang II-induced phenylalanine incorporation increased in normal hearts but did not in hypertrophied hearts. In normal hearts stimulated with Ang II, the rate of phenylalanine incorporation did not increase further during AT 2 receptor blockade. In contrast, in hypertrophied hearts stimulated with Ang II, phenylalanine incorporation was increased by AT 2 receptor blockade.
Effects of AT 2 Blockade on Ang II-Induced PKC-⑀ Translocation in Adult Rat Hearts
In normal and hypertrophied hearts with no drug, the membrane fraction of PKC composed 41.6Ϯ2.7% and 46.3Ϯ1.3% of total PKC content (PϭNS). Normal hearts stimulated with Ang II demonstrated a significant increase in membrane fraction of PKC (24.9Ϯ8.6% versus no drug, PϽ0.05) that was not further modified by AT 2 blockade (25.5Ϯ5.8% versus no drug, Figure 2 , left). In hypertrophied hearts, Ang II alone did not cause a significant increase in membrane translocation of PKC (8.8Ϯ4.1% versus no drug, Figure 2 , 
Weight and Hemodynamics of Isolated Hypertrophied and Normal Hearts
Effects of AT 2 Blockade on LV cGMP Content
In both normal and hypertrophied hearts stimulated with Ang II, selective AT 2 blockade significantly depressed LV cGMP levels (98.6Ϯ7.6 versus 64.7Ϯ6.1 fmol/mg protein, PϽ0.05, and 75.5Ϯ11.9 versus 45.8Ϯ6.2 fmol/mg protein, PϽ0.05, respectively).
Discussion
In the present study using a well-characterized intact bufferperfused adult heart model, we directly examined the role of upregulated LV AT 2 receptors on new cardiac protein synthesis in response to Ang II in adult hypertrophied rat hearts. Consistent with previous observations, 2,3 Ang II failed to cause an increase in new protein synthesis or PKC translocation in hypertrophied hearts. In normal hearts with a predominance of LV AT 1 receptors, 9,10 Ang II-induced new cardiac protein synthesis did not increase further during selective AT 2 blockade. In contrast, in hypertrophied hearts, AT 2 receptor blockade increased Ang II-induced LV protein synthesis and PKC translocation. Thus, these data support the hypothesis that AT 2 receptor activation mediates inhibitory effects on acute growth response to Ang II in adult intact hearts with LV hypertrophy.
Recent studies suggested that AT 2 receptor-related biological effects are due to activation of kinins and intracellular cGMP signaling. [13] [14] [15] [16] [17] Our data corroborate these findings by demonstrating that AT 2 blockade causes a decrease in LV cGMP content in intact hearts stimulated by Ang II. In addition, AT 2 blockade amplified PKC translocation in hypertrophied hearts stimulated with Ang II. Of note, this effect was absent in normal hearts. The presence of cross talk between PKC translocation and selective AT 2 blockade in hypertrophied hearts with upregulated AT 2 receptors 9 -12 is consistent with a report of Yamada et al, 24 who demonstrated that AT 2 receptor activation inhibits mitogen-activated protein kinase. In addition, several authors proposed that AT 2 receptor activation may enhance apoptotic cell death. 17, 24 These hypotheses merit future studies in the present aortic stenosis model of chronic LV hypertrophy and failure.
The present study has several limitations. First, the isolated-perfused heart model does not allow investigation of later components of the growth response, namely myocyte hypertrophy. Second, it does not distinguish whether changes in protein synthesis or PKC translocation are localized predominantly to cardiac myocytes or also to matrix cells that express Ang II receptors.
In summary, the present study shows that AT 2 receptor blockade amplifies new cardiac protein synthesis in response to Ang II in hypertrophied hearts. This appears to be related to both augmented PKC activation by Ang II and suppression of cGMP signaling. Thus, these data suggest for the first time that the AT 2 receptor upregulation in chronic LV hypertrophy may blunt the acute LV growth response to Ang II. The beneficial or detrimental effects of chronic AT 2 receptor blockade on hypertrophic remodeling and the transition to failure in pressure-overload hypertrophy remain to be investigated. 
